Scientific discoveries are being unlocked at a faster rate than ever before – resulting in the development of many new medicines. We are on the cusp of multiple breakthroughs in the treatment of complex acute and chronic conditions, from cancer, diabetes and cardiac disease to rheumatoid arthritis depression and dementia.

As the complexity of these medicines increases – and as a wave of revolutionary diagnostic tools unlock a new era of precision medicine – capturing the full system value of breakthrough drugs is becoming harder and harder. 

These new medicines present an incredible opportunity to improve health outcomes across Canada, but payers and policymakers are concerned about the complexity of rolling out these therapies across over-burdened health systems. This problem is compounded by the fact that many breakthrough treatments are extremely expensive – raising the stakes for the health system leaders debating both their reimbursement and their utilization.

Focused on accelerating the path from “Idea to Utilization,” I2U is an initiative, made possible by Novartis Canada, that is committed to offering health system leaders the knowledge, support and information they need to be better capture the full value of future breakthrough medicines.